Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One pill to rule them all? polypill aims to boost heart drug adherence

NCT ID NCT05514938

Disease control Sponsor: University of Texas Southwestern Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 20, 2026 · Updated 2 times

Summary

This completed Phase 2 trial tested whether a single daily polypill (containing a statin, aspirin, and a blood thinner) could improve medication adherence in 140 patients who had a heart attack and received a stent. The study compared the polypill to usual care with separate pills. The goal was to see if the polypill helped patients stick to their medications and improved cholesterol and blood clotting levels at one month.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Polypill (rosuvastatin, aspirin, and either clopidogrel or prasugrel)
What this could lead to
If it works, this could simplify post-heart-attack care by combining multiple daily pills into one, making it easier for patients to stick with their medications and potentially reducing future heart problems.
What could go wrong
This is a small, early-phase study (140 participants) focused on short-term lab results, not long-term outcomes like survival. The polypill may not work for everyone, and side effects from the combined drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

140 people

The number who actually took part.

Started

Nov 2022

Finished

Jun 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1\. Patients admitted with acute coronary syndrome who undergo percutaneous coronary intervention with drug eluting stent placement. Exclusion Criteria: 1. Age \< 18 2. Estimated glomerular filtration rate \< 30 mL/min/1.73 m2 as measured by the simplified MDRD formula 3. Current need for inotropes or with cardiac index \< 2.2 L/min/m2 4. Current need for systemic anticoagulation 5. Contraindication to receive any components of the polypill 6. History of allergic reaction or intolerance to aspirin, prasugrel or clopidogrel, or rosuvastatin 7. Comorbidities that might be expected to limit lifespan within the 1-month study period 8. Inability to provide written informed consent 9. Pregnancy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute coronary syndrome are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome coronary artery disorder hyperlipidemia Lipid Metabolism Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute coronary syndrome Coronary artery disease Lipid disorder

Contacts and locations

Locations

  • UT Southwestern Medical Center

    Dallas, Texas, 75235, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.